LRMR insider transaction filings
Larimar Therapeutics, Inc. — 38 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-07-08. Screen LRMR transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 1 Form 4 filing. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 1 leg across 1 filing by 1 insider — 50,000 shares, $166,890 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 0.
- Largest priced transaction: purchase of 50,000 shares @ $3.34 ($166,890) by Hamilton Thomas Edward, filed 2026-07-08.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Hamilton Thomas Edward — Director | 1 | 1 leg · 50,000 sh · $166,890 | — | — |
Recent Form 4 filings — Larimar Therapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-08 | 4 | Hamilton Thomas Edward — Director | Purchase (P): 50,000 @ $3.34 | EDGAR |
| 2026-05-20 | 4 | Truitt Joseph — Director | Grant/award (A): 55,150 (derivative) @ $0 | EDGAR |
| 2026-05-20 | 4 | Hamilton Thomas Edward — Director | Grant/award (A): 55,150 (derivative) @ $0 | EDGAR |
| 2026-05-20 | 4 | THOMAS FRANK E — Director | Grant/award (A): 55,150 (derivative) @ $0 | EDGAR |
| 2026-05-20 | 4 | SHERMAN JEFFREY W — Director | Grant/award (A): 55,150 (derivative) @ $0 | EDGAR |
| 2026-05-20 | 4 | LEFF JONATHAN S — Director | Grant/award (A): 55,150 (derivative) @ $0 | EDGAR |
| 2026-05-20 | 4 | Flynn James E — Director, 10% owner DEERFIELD MANAGEMENT COMPANY, L.P. — Director, 10% owner | Grant/award (A): 55,150 (derivative) @ $0 | EDGAR |
| 2026-03-02 | 4 | Hamilton Thomas Edward — Director | Purchase (P): 100,000 @ $5 | EDGAR |
| 2026-03-02 | 4 | THOMAS FRANK E — Director | Purchase (P): 5,000 @ $5 | EDGAR |
| 2026-03-02 | 4 | SHERMAN JEFFREY W — Director | Purchase (P): 5,000 @ $5 | EDGAR |
| 2026-03-02 | 4 | Flynn James E — Director, 10% owner DEERFIELD MANAGEMENT COMPANY, L.P. — Director, 10% owner Deerfield Mgmt III, L.P. — Director, 10% owner Deerfield Mgmt HIF, L.P. — Director, 10% owner Deerfield Mgmt IV, L.P. — Director, 10% owner Deerfield Mgmt L.P. — Director, 10% owner Deerfield Private Design Fund III, L.P. — Director, 10% owner Deerfield Healthcare Innovations Fund, L.P. — Director, 10% owner Deerfield Private Design Fund IV, L.P. — Director, 10% owner DEERFIELD PARTNERS, L.P. — Director, 10% owner | Purchase (P): 1,084,010 @ $5 · Purchase (P): 1,084,012 @ $5 · Purchase (P): 831,978 @ $5 · Purchase (P): 2,000,000 @ $5 | EDGAR |
| 2026-01-27 | 4 | Shankar Gopi — Chief Development Officer | Grant/award (A): 25,637 @ $0 · Grant/award (A): 153,822 (derivative) @ $0 | EDGAR |
| 2026-01-27 | 4 | Clayton Russell — Chief Medical Officer | Grant/award (A): 25,637 @ $0 · Grant/award (A): 153,822 (derivative) @ $0 | EDGAR |
| 2026-01-27 | 4 | BEN-MAIMON CAROLE — President and CEO, Director | Grant/award (A): 100,100 @ $0 · Grant/award (A): 600,600 (derivative) @ $0 | EDGAR |
| 2026-01-27 | 4 | Celano Michael — Chief Financial Officer | Grant/award (A): 37,604 @ $0 · Grant/award (A): 225,622 (derivative) @ $0 | EDGAR |
| 2025-08-04 | 4 | Flynn James E — Director, 10% owner DEERFIELD MANAGEMENT COMPANY, L.P. — Director, 10% owner Deerfield Mgmt III, L.P. — Director, 10% owner Deerfield Mgmt HIF, L.P. — Director, 10% owner Deerfield Mgmt IV, L.P. — Director, 10% owner Deerfield Mgmt L.P. — Director, 10% owner Deerfield Private Design Fund III, L.P. — Director, 10% owner Deerfield Healthcare Innovations Fund, L.P. — Director, 10% owner Deerfield Private Design Fund IV, L.P. — Director, 10% owner DEERFIELD PARTNERS, L.P. — Director, 10% owner | Purchase (P): 3,387,529 @ $3.20 · Purchase (P): 3,387,539 @ $3.20 · Purchase (P): 2,599,932 @ $3.20 | EDGAR |
| 2025-05-15 | 4 | Flynn James E — Director, 10% owner DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) — Director, 10% owner | Grant/award (A): 19,000 (derivative) @ $0 | EDGAR |
| 2025-05-14 | 4 | Truitt Joseph — Director | Grant/award (A): 19,000 (derivative) @ $0 | EDGAR |
| 2025-05-14 | 4 | Hamilton Thomas Edward — Director | Grant/award (A): 19,000 (derivative) @ $0 | EDGAR |
| 2025-05-14 | 4 | THOMAS FRANK E — Director | Grant/award (A): 19,000 (derivative) @ $0 | EDGAR |
| 2025-05-14 | 4 | SHERMAN JEFFREY W — Director | Grant/award (A): 19,000 (derivative) @ $0 | EDGAR |
| 2025-05-14 | 4 | LEFF JONATHAN S — Director | Grant/award (A): 19,000 (derivative) @ $0 | EDGAR |
| 2025-01-24 | 4 | Shankar Gopi — Chief Development Officer | Grant/award (A): 23,306 @ $0 · Grant/award (A): 139,838 (derivative) @ $0 | EDGAR |
| 2025-01-24 | 4 | Clayton Russell — Chief Medical Officer | Grant/award (A): 23,306 @ $0 · Grant/award (A): 139,838 (derivative) @ $0 | EDGAR |
| 2025-01-24 | 4 | BEN-MAIMON CAROLE — President and CEO, Director | Grant/award (A): 91,000 @ $0 · Grant/award (A): 546,000 (derivative) @ $0 | EDGAR |
| 2025-01-24 | 4 | Celano Michael — Chief Financial Officer | Grant/award (A): 34,185 @ $0 · Grant/award (A): 205,111 (derivative) @ $0 | EDGAR |
| 2024-06-03 | 4 | Flynn James E — Director, 10% owner DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) — Director, 10% owner | Grant/award (A): 19,000 (derivative) @ $0 | EDGAR |
| 2024-05-31 | 4 | Truitt Joseph — Director | Grant/award (A): 19,000 (derivative) @ $0 | EDGAR |
| 2024-05-31 | 4 | Hamilton Thomas Edward — Director | Purchase (P): 57,208 @ $8.74 · Grant/award (A): 19,000 (derivative) @ $0 | EDGAR |
| 2024-05-31 | 4 | THOMAS FRANK E — Director | Grant/award (A): 19,000 (derivative) @ $0 | EDGAR |
| 2024-05-31 | 4 | SHERMAN JEFFREY W — Director | Grant/award (A): 19,000 (derivative) @ $0 | EDGAR |
| 2024-05-31 | 4 | LEFF JONATHAN S — Director | Grant/award (A): 19,000 (derivative) @ $0 | EDGAR |
| 2024-02-16 | 4 | Flynn James E — Director, 10% owner DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) — Director, 10% owner Deerfield Mgmt III, L.P. — Director, 10% owner Deerfield Mgmt HIF, L.P. — Director, 10% owner Deerfield Mgmt IV, L.P. — Director, 10% owner Deerfield Mgmt L.P. — Director, 10% owner Deerfield Private Design Fund III, L.P. — Director, 10% owner Deerfield Healthcare Innovations Fund, L.P. — Director, 10% owner Deerfield Private Design Fund IV, L.P. — Director, 10% owner DEERFIELD PARTNERS, L.P. — Director, 10% owner | Purchase (P): 1,430,206 @ $8.74 · Purchase (P): 1,430,206 @ $8.74 · Purchase (P): 1,430,205 @ $8.74 | EDGAR |
| 2024-02-15 | 4 | THOMAS FRANK E — Director | Purchase (P): 2,000 @ $11 | EDGAR |
| 2024-01-19 | 4 | Shankar Gopi — Chief Development Officer | Grant/award (A): 22,500 @ $0 · Grant/award (A): 135,000 (derivative) @ $0 | EDGAR |
| 2024-01-19 | 4 | Celano Michael — Chief Financial Officer | Grant/award (A): 31,250 @ $0 · Grant/award (A): 187,500 (derivative) @ $0 | EDGAR |
| 2024-01-19 | 4 | Clayton Russell — Chief Medical Officer | Grant/award (A): 22,500 @ $0 · Grant/award (A): 135,000 (derivative) @ $0 | EDGAR |
| 2024-01-19 | 4 | BEN-MAIMON CAROLE — President and CEO, Director | Grant/award (A): 66,125 @ $0 · Grant/award (A): 396,750 (derivative) @ $0 | EDGAR |
Recent 8-K events — Larimar Therapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-04 | 8-K | 2.02 — Results of Operations and Financial Condition 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-29 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-19 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-14 | 8-K | 2.02 — Results of Operations and Financial Condition 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-19 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-09 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-27 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-24 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-22 | 8-K | 3.02 — Unregistered Sales of Equity Securities 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-12 | 8-K | 2.02 — Results of Operations and Financial Condition 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=LRMR returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →